The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients: a protocol for an UNLOCK study from the IPCRG

dc.contributor.authorStällberg, Björnpor
dc.contributor.authorTeixeira, Pedro Miguel Silva Costa Afonsopor
dc.contributor.authorBlom, Coert
dc.contributor.authorLisspers, Karin
dc.contributor.authorTsiligianni, Ioanna
dc.contributor.authorJordan, Rachel
dc.contributor.authorRomán, Miguel
dc.contributor.authorKleefstra, Nanne
dc.contributor.authorKorzh, Oleksii
dc.contributor.authorPrice, David
dc.contributor.authorChavannes, Niels
dc.date.accessioned2017-07-28T12:15:02Z
dc.date.available2017-07-28T12:15:02Z
dc.date.issued2016
dc.date.submitted2015
dc.date.updated2017-07-21T09:12:05Z
dc.description.abstract[Abstract] Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality with high social and economic costs. The prevalence of COPD has been reported to vary between 6 and 26.1% worldwide.1 COPD has also been associated with a high prevalence of one or more comorbid conditions, which have an impact on health status and mortality.2–5 Although several diseases have been studied as COPD comorbidities6,7 few studies have looked at the issue of multimorbidity in COPD.8–10 COPD, like other chronic disorders, has been associated with comorbidities that increase in number and severity with age, and are more prevalent among deprived social groups.5,8 There is evidence that comorbidities increase the risk for exacerbations, reduce health status, and increase the risk of mortality.5,8 COPD guidelines (e.g., GOLD recommendations) still consider the diagnosis and management of comorbidities from an individual disease point of view.11 Consequently, health services focus on individual diseases rather than multimorbidity.10–13 A better knowledge of the prevalence and impact of multimorbidity facing COPD patients in primary care would help to evaluate whether a different approach (i.e., multimorbidity) should be taken. [...]eng
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersionpor
dc.description.sponsorshipThe IPCRG provided funding for this research project as an UNLOCK Group study for which the funding was obtained through an unrestricted grant by Novartis AG, Basel, Switzerland. Novartis has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study will include data from the Optimum Patient Care Research Database, and is undertaken in collaboration with Optimum Patient Care and the Respiratory Effectiveness Group, which will provide the data for this initiative without charge to the UNLOCK Group.por
dc.identifier.doi10.1038/npjpcrm.2016.69por
dc.identifier.issn2055-1010por
dc.identifier.pmid27853173por
dc.identifier.urihttps://hdl.handle.net/1822/46306
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherNature Publishing Group
dc.relation.publisherversionhttp://www.nature.com/npjpcrm/por
dc.rightsopenAccesspor
dc.subject.wosScience & Technologypor
dc.titleThe prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients: a protocol for an UNLOCK study from the IPCRGpor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationVolume26por
sdum.journalnpj Primary Care Respiratory Medicinepor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
the prevalence of comorbidities in copd patients.pdf
Tamanho:
237.7 KB
Formato:
Adobe Portable Document Format